

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Yoram REITER et al

Serial No.:

10/510,229

Filed:

October 13, 2004

For:

ANTIGEN-PRESENTING COMPLEX-BINDING

COMPOSITIONS AND USES THEREOF

Examiner:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Group Art Unit: Not yet available

Attorney.

Docket: 28429

JC03 Rec'd PCT/PTO 1 4 SEP 2009

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Nartin a Maynihan

Martin Moynihan

Registration No. 40,338

Dated: August 28, 2005

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

WILL TO				•	Complete if Known				
Substitute for form 1449A/PTO INFORMATION DISCLOSURE					Application Number	10/51	10,229		
					Filing Date	October 13, 2004			
	STATEMENT BY APPLICANT				First Named Inventor	REITER Yoram et al			
(use as many sheets as necessary)					Art Unit	Not yet available			
					Examiner Name				
Sheet			of		Attorney Docket Number	2842	9		
U.S. PATENT DOCUMENTS									
Examiner Initials*	Cite No. 1	Document Number Number-Kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
-	1	US-5,952,471	09-14-19	999	Griffiths Lawson				
***	2	US-6,416,738	09-9-2002		Theodore et al.		***		
	3	US-2003/0165993	04-4-2003		Buechler et al.				
4		US-5,591,829	07-7-1997		Matsushita				
•	5	US-2003/0129191	07-10-20		Theodore et al.				
	6	US-2003/0223994	04-4-2003		Hoogenboom et al.				
	7	US-5,695,928	09-9-19	97	Stewart et al.				
	<u> </u>								
							-		
	!								
	-		-						
	-		-						
	-								

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. 1	Foreign Patent Documents Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6		
	8	PCT WO 2004/084798	07-7-2004	Reiter et al.				
						₩		
						┼		
- -						╁		
	-					\Box		
Examiner				Date				
Signature				Considered				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

TO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

Complete if Known					
Application Number	10/510,229				
Filing Date	October 10, 2004				
First Named Inventor	REITER Yoram et al				
Group Art Unit	Not yet available				
Examiner Name					

	STA	TEMENT BY APPLICANT	Group Art Unit Not yet available						
		(use as many sheets as necessary)	Examiner Name	110t jot avanable					
G1 ·		<u> </u>	D 1 1 1	1 20120					
Sheet		OTHER PRIOR ART, NOVERATENT LITER	Attorney Docket Number	28429					
Examiner	Cite	OTHER PRIOR ART – NON PATENT LITER							
Initials	No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.							
	9	Reiter et al. "Peptide-Specific Killing of Antigen-Presenting Cells by A Recombinant							
		Antibody-Toxin Fusion Protein Targeted to Major Hist							
		Complex/Peptide Class I Complexes With T Cell Rece	ptor-Like Specifity", Pro	oc.					
	10	Natl. Acad. Sci. USA, 94(9): 4631-4636, 1997.	6 .6 14 .						
	10	Andersen et al. "A Recombinant Antibody With the Ar Histocompatibility Complex-Restricted Specifity of T							
		National Academy of Sciences, 93(5): 1820-1824, 1996		ie					
	11								
	111	Rudikoff et al. "Single Amino Acid Substitution Altering Antigen-Binding Specifity", Proceedings of the National Academy of Sciences, USA, 79(6): 1979-							
		1983, 1982.	1011003, 05/1, 77(0). 17/						
	12	Stedman Definition "Fab Fragment", Stedman's Online	Medical Dictionary, 27	th					
		Edition. Www.stedmans.com.	,,						
	13	??? Definition "Fab", The Online Medical Ddictionary,	cancerweb.ncl.ac.uk/or	nd/.					
	14	Engberg et al. "Recombinent Antibodies With the Anti							
		Specifity of T Cells: Novel Reagents for Basic and Clir							
		Immunotherpy", Immunotechnology, 4(Nos.3-4): 273-2	278, 1999.						
	15	Saito et al. "In Vivo Selection of T-Cell Receptor Junct	ional Region Sequences	s by					
		HLA-A2 Human T-Cell Lymphotropic Virus Type 1 T	ax11-19 Peptide Compl	exes",					
	16	Journal of Virology, 75(2): 1065-1071, 2001.	TA 1 1 TI OD 1						
	16	Polakova et al. "Antibodies Directed Against the MHC-I Molecule H-2Dd Complexed With An Antigenic Peptide: Similarities to A T Cell Receptor With the							
		Same Specifity", The Journal of Immunology, 165: 570		i the					
	17	Chung et al. "Competitive Inhibition In Vivo and Skew		oire of					
	1′	Antigen-Specific CTL Priming by an Anti-Peptide-MHC Monoclonal Antbody", The							
		Journal of Immunology, 167: 699-707, 2001.	ie monocional i incode	, 1110					
	18	Robert et al. "Antibody-Conjugated MHC Class I Tetra	mers Can Target Tumo	r Cells					
		For Specific Iysis by T Lumphocytes", European Journ							
		3170, 2000.							
	19	Yoshida et al. "Isolation And Characterization Of Retro							
		Human Adult T-Cell Leukemia And Its Implication In	the Disease", PNAS, 79	:2031-					
	100	2035, 1982.							
	20	Köhler et al. "Continuous Cultures Of Fused Cells Secr	eting Antibody Of Pred	efined					
	21	Specificity", Nature, 256:495-497, 1975. Harding et al. "Quantitation Of Antigen-Presenting Cel	1 MUC Class II/ Dantida						
	21	Complexes Necessary For T-Cell Stimulation", Nature,		,					
	22	Christinck et al. "Peptide Binding To Class I MHC On		itation					
		of Compplexes Required For CTL Lysis", Nature, 352:		itation					
	23	Aharoni et al. "Immunomodulation Of Experimental A		is Bv					
		Antibodies To The Antigen-Ia Complex", Nature, 351:		·					
	24	Haard et al. "A Large Non-Immunized Human Fab Fra		nat					
		Permits Rabipd Isolation And Kinetic Analysis Of High		The					
	<u> </u>	Journal of Biological Chemistry, 274(26): 18218-18230							
	25	Winter et al. "Man-Made Antibodies", Nature, 349: 293							
	26	Stubbs et al. "Influence Of Core Fucosylation On TheF		nary					
		N-Linked Oligosaccharide", Bichemistry, 35: 937-947,							
	27	Hoogenboom et al. "By-Passing Immunisation - Human							
		Repertoires Of Germline VH Gene Segments Rearrang Molecular Biology, 227: 381-388, 1992.	ed in vitro", Journal of						
		Wiolecular Biology, 227. 301-300, 1992.							

اس ع			
1 4 2005 EF	28	Grassmann et al. "Transformation To Continuous Growth Or Primary Human T Lymphocytes By Human T-Cell Leukemia Virus Type I X-Region Genes Tranduced By A Herpesvirus Saimiri Vector", PNAS, 86: 3351-3355, 1989.	_
e TRADERA	29	Poiesz et al. "Detection And Isolation Of Type C Retrovirus Particles From Fresh And Cultured Lymphocytes Of A Patient With Cutaneous T-Cell Lymphoma", PNAS, 77(12): 7415-7419, 1980.	
	30	Porter "The Hydrolysis Of Rabbit γ-Globulin And Antibidies With Crystalline Papain", Biochemical Journal, 73: 119-126, 1959.	
	31	Pozzatti et al. "The Human T-Lymphotropic Virus Type I "Tax" Gene Can Cooperate With The "Ras" Oncogene To Induce Neoplastic Transformation Of Cells", Molecular and Cellular Biology, 10(1): 413-417, 1990.	
	32	Neuberger "Generating High-Avidity Human Mabs InMice", Nature Biotechnology, 14, 1996.	
-	33	Bird et al. "Single-Chain Antigen-Binding Proteins", Science, 242: 423-426, 1988.	-
	34	Marks et al. "By-Passing Immunization - Human Antibodies From V-Gene Libraries Displayed On Phage", Journal of Melcular Biology, 222: 581-597, 1991.	
	35	Cote et al. "Generation Of Human Monoclonal Antibodies Reactive With Cellular Antigens", PNAS, 80: 2026-2030, 1983.	
	36	Murphy et al. "A Novel MHC Class II Epitope Expressed In Thymic Medulla But Not Cortex", Nature, 338:765-768, 1989.	
	37	Riechmann et al. "Reshaping Human Antibodies For Therapy", Nature 332: 323-327, 1988.	
	38	Bieganowska et al. "Direct Analysis Of Viral-Specific CD8 T Cells With Soluble HLA-A2/Tax11-19 Tetramer Complexes in Patients With Human T-Cell Lymphotropic Virus-Associated Myelopathy", he Journal of Immunology, 162:1765-1771, 1999.	
	39	Anton et al. "MHC Class I-Associated Peptides Produced From Endogenous Gene Products With Vastly Different Efficiencies", The Journal of Immunology, 158: 2535-2542, 1997.	
	40	Altman et al. "Phenotypic Analysis Of Antegen-Specific T Lymphocytes", Science, 274:94-96, 1996.	
	41	Chames et al. "Direct Selection Of A Human Antibody Fragment Directed Against The Tumor T-Cell Epitope HLA-A1-MAGE-A1 From A Nonimmunized Phage-Fab Library", PNAS, 97(14): 7969-7974, 2000.	
	42	Demotz et al. "The Minimal Number Of Class II MHC-Antigen Complexes Needed For T Cell Activation", Science, 249: 1028-1030, 1990.	
	43	Boerner et al. "Production Of Antigen-Specific Human Monoclonal Antibodies From In-Vitro-Primed Human Splenocytes", The Journal of Immunology, 147(1): 86-95, 1991.	
	44	Morrison "Success In Specification", Nature, 368:812-813,1994.	
	45	Jones et al. "Replacing The Complementarity-Determining Regions On A Human Antibody With Those From a Mouse", Nature, 321:522-525,1986.	
	46	Verhoeyen et al. "Reshaping Human Antiodies: Grafting an Antilysozyme Activity", Science, 239: 1534-1536, 1988.	
	47	Rosenberg Nature, 411: 380-384, 2001.	
	48	Lonberg et al. "Antigen-Specific Human Antibodies From Mice Comprising Four Distinct Genetic Modifications", Nature, 368, 856-859, 1994.	
	49	Verhoeyen et al. "Reshaping Human Antibodies: Grafting An Antilysozyme Activity", Science, 239, 1534-1536,1988.	

Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional). 2. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents. P.O. Box 1450. Alexandria. VA 22313-1450. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.